Manu Chakravarthy
Technik-/Wissenschafts-/F&E-Leiter bei Carmot Therapeutics, Inc.
Aktive Positionen von Manu Chakravarthy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2021 | - |
Karriereverlauf von Manu Chakravarthy
Ehemalige bekannte Positionen von Manu Chakravarthy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AXCA HEALPAR | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2017 | 05.03.2021 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.08.2015 | 01.06.2017 |
Ausbildung von Manu Chakravarthy
Saint John's University | Undergraduate Degree |
University of Texas Graduate School of Biomedical Sciences | Doctorate Degree |
The University of Texas Medical School At Houston | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AXCA HEALPAR | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 1 |
---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Börse
- Insiders
- Manu Chakravarthy
- Erfahrung